KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2016 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
KALV on Nasdaq
Shares outstanding
50,580,036
Price per share
$16.15
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
58,631,944
Total reported value
$714,167,714
% of total 13F portfolios
0%
Share change
+4,161,279
Value change
+$51,926,495
Number of holders
143
Price from insider filings
$16.15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.9% $63,650,358 4,941,798 TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025
Frazier Life Sciences Public Fund, L.P. 6.9% +42% $42,222,226 +$12,986,864 3,466,521 +44% Frazier Life Sciences Public Fund, L.P. 01 Nov 2025
Capital World Investors 6.4% $40,927,321 3,177,587 Capital World Investors 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 5.9% +18% $39,595,019 +$5,780,725 2,963,699 +17% Millennium Management LLC 23 Dec 2025
Point72 Asset Management, L.P. 5.5% $44,930,777 2,781,902 Point72 Asset Management, L.P. 05 Jan 2026
Vestal Point Capital, LP 1.5% $9,135,000 750,000 Vestal Point Capital, LP 30 Sep 2025

As of 30 Sep 2025, 143 institutional investors reported holding 58,631,944 shares of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV). This represents 116% of the company’s total 50,580,036 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) together control 101% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VR ADVISER, LLC 13% 6,728,985 0% 4.6% $81,959,037
TANG CAPITAL MANAGEMENT LLC 10% 5,041,798 +2% 2.4% $61,409,100
Frazier Life Sciences Management, L.P. 10% 5,039,867 +3.1% 1.8% $61,385,580
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% 4,768,712 -3.8% 1.8% $58,082,912
Capital World Investors 6.3% 3,177,587 0% 0.01% $38,703,010
BlackRock, Inc. 6.2% 3,126,117 -0.11% 0% $38,076,105
VANGUARD GROUP INC 4.9% 2,501,119 +3.7% 0% $30,463,629
MILLENNIUM MANAGEMENT LLC 4.1% 2,096,223 +515% 0.02% $25,531,996
Woodline Partners LP 3.8% 1,920,664 0% 0.11% $23,393,688
GOLDMAN SACHS GROUP INC 3.6% 1,800,181 +1239% 0% $21,926,205
Parkman Healthcare Partners LLC 3.4% 1,735,003 +155% 2.3% $21,132,337
STATE STREET CORP 3.1% 1,575,496 +17% 0% $19,189,541
SILVERARC CAPITAL MANAGEMENT, LLC 2.7% 1,363,378 -26% 2.4% $16,605,944
EMERALD ADVISERS, LLC 2.7% 1,351,254 +30% 0.53% $16,458,274
Octagon Capital Advisors LP 2.5% 1,273,333 0% 2.4% $15,509,196
SCHRODER INVESTMENT MANAGEMENT GROUP 2.3% 1,158,457 +109% 0.01% $14,144,760
GEODE CAPITAL MANAGEMENT, LLC 1.8% 928,671 -1.3% 0% $11,313,517
EMERALD MUTUAL FUND ADVISERS TRUST 1.8% 917,975 +19% 0.58% $11,180,936
Vestal Point Capital, LP 1.5% 750,000 -84% 0.41% $9,135,000
Freestone Grove Partners LP 1.4% 704,448 0.06% $8,580,177
Sio Capital Management, LLC 1.4% 683,819 2.1% $8,328,915
Kynam Capital Management, LP 1.2% 606,171 0.55% $7,383,163
Bank of New York Mellon Corp 1.2% 596,474 +454% 0% $7,265,054
BARCLAYS PLC 1.1% 577,904 +242% 0% $7,038,871
MORGAN STANLEY 1.1% 564,855 +136% 0% $6,879,937

Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 407,158 $6,575,918 +$2,953,548 $16.15 8
2025 Q3 58,631,944 $714,167,714 +$51,926,495 $12.18 143
2025 Q2 54,445,883 $615,513,091 -$5,352,606 $11.30 138
2025 Q1 54,890,685 $633,782,153 +$5,364,849 $11.54 127
2024 Q4 55,190,249 $467,414,520 +$30,397,001 $8.47 129
2024 Q3 48,412,221 $560,958,769 +$549,019 $11.58 120
2024 Q2 48,235,227 $568,211,775 +$14,329,598 $11.78 118
2024 Q1 46,978,393 $557,162,578 +$117,921,974 $11.86 128
2023 Q4 36,983,052 $453,043,903 +$5,790,575 $12.25 92
2023 Q3 36,263,336 $349,220,877 +$17,912,528 $9.63 101
2023 Q2 34,451,516 $310,062,547 +$8,864,955 $9.00 93
2023 Q1 33,720,468 $265,039,035 -$7,240,065 $7.86 87
2022 Q4 33,810,837 $228,557,857 +$23,549,577 $6.76 88
2022 Q3 25,639,454 $372,024,783 +$16,611,056 $14.51 88
2022 Q2 24,252,971 $238,647,172 -$18,209,799 $9.84 84
2022 Q1 23,950,478 $353,046,504 -$11,733,222 $14.74 84
2021 Q4 23,784,064 $314,614,009 -$24,155,895 $13.23 93
2021 Q3 23,380,949 $408,241,803 -$21,548,932 $17.45 101
2021 Q2 24,320,398 $582,722,986 +$12,095,008 $23.96 108
2021 Q1 23,504,843 $603,806,496 +$241,335,972 $25.69 115
2020 Q4 14,665,664 $278,488,932 +$4,362,596 $18.99 79
2020 Q3 16,200,799 $203,913,450 +$2,818,589 $12.59 61
2020 Q2 15,986,858 $193,667,544 +$9,419,888 $12.10 72
2020 Q1 15,660,431 $119,795,221 +$17,243,054 $7.65 68
2019 Q4 13,721,637 $244,359,076 +$13,370,440 $17.81 73
2019 Q3 13,183,569 $152,927,098 -$33,989,311 $11.60 75
2019 Q2 14,786,402 $327,505,666 +$6,277,733 $22.15 74
2019 Q1 13,905,857 $397,892,000 +$23,850,655 $28.62 67
2018 Q4 12,995,790 $256,399,000 +$7,695,219 $19.75 56
2018 Q3 12,319,459 $272,385,000 +$112,676,598 $22.11 46
2018 Q2 6,316,266 $51,280,000 -$1,600,370 $8.12 24
2018 Q1 6,502,232 $61,590,000 +$133,882 $9.48 23
2017 Q4 6,484,043 $63,213,000 -$2,998,314 $9.75 23
2017 Q3 7,715,060 $52,230,000 +$2,314,839 $6.73 15
2017 Q2 7,368,527 $54,075,000 -$1,766,461 $7.36 17
2017 Q1 7,587,480 $59,162,000 +$2,023,038 $7.81 18
2016 Q4 7,331,083 $51,493,000 +$46,974,000 $7.07 18